Primary sclerosing cholangitis (PSC) is a disease of the liver that causes inflammation of the bile ducts and scarring (fibrosis). These conduits are tubes that allow fluids from the liver (bile) to pass through the colon, allowing fat to break down. Men between the ages of 25 and 40 are disproportionately affected by this disease. Damage to the ducts causes bile acids, which are key components of bile, to build up in the liver, causing liver tissue damage, portal hypertension (high blood pressure in the veins connecting the liver and intestine) and liver failure, as well as an increased risk of liver cancer.
Get a sample report with the latest information @
A comprehensive study on the impact of the Covid-19 pandemic on the global primary sclerosing cholangitis market is also written in the report. More than five products are currently in phase 2 clinical studies, some of them showing promising results. Intercept Pharmaceuticals, Inc., for example, is conducting the ASEOP study, which studies obeticholic acid (OCA) for primary sclerosing cholangitis. In February 2016, Shire Plc. has completed a Phase 2 clinical trial for the therapeutic candidate LUM001.
These potential compounds would be among the first to receive regulatory approval for this condition if they pass the advanced clinical trials phase (i.e. Phase 3) and gain regulatory approval.
In addition, the majority of patients live in developed economies such as Europe and North America, where diagnostic rates and accessibility are generally higher than in emerging economies such as Asia-Pacific, resulting in a higher rate of adoption of new products with significantly higher annual costs (ie over US $ 50,000 for orphan drugs). Due to the above-mentioned factors, the Global Primary Sclerosing Cholangitis Market is expected to reach US $ 140.4 million by 2023.
However, the withdrawal of potential therapeutic compounds from late-stage clinical trials has limited the availability of effective treatment, forcing patients to turn to bile acid sequestrants, antibiotics, antihistamines, opioid antagonists, and ursodeoxycholic acid as alternatives (UDCA).
Current medicinal interventions, such as ursodeoxycholic acid, improve liver enzymes, according to a study published in the Gastroenterology and Hepatology Journal in 2016. However, this does not prevent PSC from progressing or reduce the risk of recurrence. Thus, the unavailability of approved drugs targeting the disease in practical medical use is a factor hampering the growth of the global primary sclerosing cholangitis market.
You want to “get ahead” with your competitors, ask for a PDF brochure with the latest information @
Rising frequency of PSC-related disorders, such as liver cancer and inflammatory bowel disease, is likely to boost therapeutic acceptance of effective pharmaceuticals to treat the disease, propelling the primary sclerosing cholangitis market forward. Inflammatory bowel disease (IBD) is detected in 50 to 80% of patients with PSC, according to the World Journal of Gastroenterology, with ulcerative colitis (UC) accounting for 80 to 90% of these cases.
In addition, people with PSC are more likely than the general population to develop cholangiocarcinoma, a cancer of the bile ducts. According to the National Organization for Rare Diseases (NORD), about 8 to 15% of patients with PSC develop cholangiocarcinoma and are at increased risk of gallbladder cancer. Patients with PSC are also more likely to develop Crohn’s disease, colon cancer, and immune-mediated diseases such as thyroid disease, Peyronie’s disease, retroperitoneal fibrosis, psoriasis, rheumatoid arthritis. , celiac disease and others, according to NORD.
Currently, liver transplantation is the only known cure for primary sclerosing cholangitis and is one of the leading causes of liver transplantation in the United States. patients, thus demanding effective and affordable therapeutic solutions to meet unmet patient needs. According to the United Network for Organ Sharing (UNOS), 2011, the estimated billing costs for a liver transplant procedure are approximately US $ 577,100 in the United States.
Due to the high costs associated with liver transplantation, as well as the increased risk factors leading to the development of important diseases, the adoption of PSC drugs is likely to increase, stimulating the expansion of the market in the near future.
The major players operating in the Global Primary Sclerosing Cholangitis Market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc. ., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc. and Shenzhen HighTide Biopharmaceutical Ltd.
Reasons to buy this report
• Current and future prospects of the Global Primary Sclerosing Cholangitis Market in both developed and emerging markets
• The segment which is expected to dominate the market as well as the segment which holds the highest CAGR during the forecast period.
• Regions / countries expected to experience the fastest growth rates during the forecast period
• The latest developments, market shares and strategies used by the main market players
Buy this Complete an activity report with a discount of US $ 2000 @
Global Primary Sclerosing Cholangitis Market Research Report
Section 1: Global Primary Sclerosing Cholangitis Industry Overview
Section 2: Global Economic Impact on Primary Sclerosing Cholangitis Industry
Section 3: Competition in the world market by industry producers
Section 4: World Productions, Revenue (Value), by Region
Section 5: Global Supply (Production), Consumption, Export, Import, Geographically
Section 6: World Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, Based on Application
Section 8: Primary Sclerosing Cholangitis Market Price Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients from all walks of life, from Fortune 500 companies and nonprofits to startups looking to enter the market. We excel in providing unmatched actionable market insights across various industry verticals including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, customized research solutions and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837